APA (7th ed.) Citation

Sonehara, K., Tateishi, K., Yoh, K., Usui, K., Hosomi, Y., Kishi, K., . . . Kunitoh, H. Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Wiley.

Chicago Style (17th ed.) Citation

Sonehara, Kei, et al. Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Wiley.

MLA (9th ed.) Citation

Sonehara, Kei, et al. Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study. Wiley.